Home Blog of Signal Transduction NF-κB TNF-alpha The binding of mutant p53 and DAB2IP increase the invasion of inflammation induced cancer cells

Category

Archives

Popular Post

ESKM, a novel therapeutic agent for sensitive and resistant PH+ leukemias

The mechanism of resistance to JAK2 inhibitor in myeloproliferative neoplasms patients

Effects of PARP inhibitors in BRCA gene-mutated ovarian cancer

DASATINIB; An inhibitor of Receptor Tyrosine Kinase

GP130/JAK/STAT3 signaling pathway induces multiple myeloma

The binding of mutant p53 and DAB2IP increase the invasion of inflammation induced cancer cells

 

One of the important characteristics of cancer development is inflammation. However, due to the complex relationship between signaling molecules, the mechanism of how inflammation is linked to cancer is not very clear. Minin et al. inflammatory cytokines can increase the invasive behavior of cancer cells with p53 missense mutants (mutp53). The article was published on Molecular Cell, recently.

 

The mutation of p53, as a tumor suppressor, is always happened in cancer. Therefore, mutp53 is an important target for cancer study, and it is reported to drive inflammation induced cancer formation and development, in previous and this study, respectively. The action that inflammatory cytokine can increase aggressiveness of mutp53 cancer cell is assisted by chemokines. Further investigation of the mechanism showed mutp53 supported NF-κB signaling activation and reduce the activity of ASK1/JNK signaling by TNFα. Mutp53 functions through interacting and inhibiting the tumor suppressor RasGAP Disabled 2 Interacting Protein (DAB2IP). Moreover, the interference of the binding of mutp53-DAB2IP reduce the invasion of cancer cells in xenografts ,indicating mutp53/DAB2IP might be a promising target in therapy of mutp53 cancers.

 

Reference:
Mol Cell. 2014 Dec 4;56(5):617-29.

Related Products

Cat.No. Product Name Information
S1029 Lenalidomide Lenalidomide is a TNF-α secretion inhibitor with IC50 of 13 nM in PBMCs. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide promotes cleaved caspase-3 expression and inhibit VEGF expression and induces apoptosis.
S7414 Caffeic Acid Phenethyl Ester Caffeic acid phenethyl ester (CAPE, Phenylethyl Caffeate) is a potent and specific inhibitor of NF-κB activation, and also displays antioxidant, immunomodulatory and antiinflammatory activities.

Related Targets

TNF-alpha NF-κB